Deal Spotlight
Jul 13, 2026July 13, 2026
Colossal Biosciences raises €55.2M seed round with Thomas Tull
€55.2M
round size
series-a
stage
The funding round closed on June 19, 2026, with participation from Breyer Capital, Draper Associates, Richard Garriott, Tim Draper, Tony Robbins, and Winklevoss Capital. The company has raised a total of €184M to date.
Colossal Biosciences is a biotechnology firm focused on de-extinction and species preservation, utilizing gene-editing technology. It is headquartered in the United States and operates in the Healthcare & Life Sciences sector at the series-a stage.
Related insights
- Cross-Country AnalysisSpain's Seed Startups Show Higher Single-Round Share Than Switzerland
- Data AnalysisThe First Cheque Is Not an Angel’s: Czech Founders Bootstrap or Take a Grant First
- Deal SpotlightHeadline raises EUR30.42M Seed backed by British Business Bank
- Deal SpotlightHadrian raises EUR35.68M Series B with ForgePoint Capital, HV Capital and others
Explore the full dataset
Brouky tracks 37,000+ investors and 122,000+ investments across 134,000+ startups. Search by country, stage, and sector.